Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2025
Principal Executive Offices: West Seattle, WA
Trading Symbol: OMER (Nasdaq Stock Market LLC)
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is regulatory in nature rather than financial:
- Regulatory Acceptance: On May 6, 2025, the U.S. Food and Drug Administration (FDA) accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab.
- Indication: The application is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA acceptance but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the text of this 8-K.
Contingencies: The acceptance of the BLA resubmission is a critical contingency for the commercialization of narsoplimab, pending the FDA's review outcome.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for details on the FDA review timeline.
- Confirm the specific indications and patient population for narsoplimab in the resubmitted BLA.
- Monitor subsequent filings for the FDA's decision on the BLA review.
- Review the company's most recent 10-K or 10-Q for current financial health and cash runway, as this 8-K contains no financial data.